×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
STOK – stoke therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
STOK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
11:12 am
stok
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
Low
Report
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
11/8
11:57 am
stok
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade [Yahoo! Finance]
11/6
08:07 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
11/6
08:07 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
11/6
07:21 am
stok
Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues [Yahoo! Finance]
Medium
Report
Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues [Yahoo! Finance]
11/5
07:00 am
stok
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Medium
Report
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
10/15
07:50 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/14
09:02 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $18.00 price target on the stock.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $18.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
09:01 pm
stok
Form SC 13G/A Stoke Therapeutics, Inc. Filed by: Redmile Group, LLC
High
Report
Form SC 13G/A Stoke Therapeutics, Inc. Filed by: Redmile Group, LLC
11/14
04:25 pm
stok
Form SC 13G Stoke Therapeutics, Inc. Filed by: BAKER BROS. ADVISORS LP
High
Report
Form SC 13G Stoke Therapeutics, Inc. Filed by: BAKER BROS. ADVISORS LP
11/14
09:00 am
stok
Form SC 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP
Medium
Report
Form SC 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP
11/12
05:57 pm
stok
Form SC 13G/A Stoke Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Stoke Therapeutics, Inc. Filed by: VANGUARD GROUP INC
11/5
04:16 pm
stok
Form 4 Stoke Therapeutics, Inc. For: Nov 01 Filed by: Ticho Barry
Low
Report
Form 4 Stoke Therapeutics, Inc. For: Nov 01 Filed by: Ticho Barry
11/5
04:06 pm
stok
Form 10-Q Stoke Therapeutics, Inc. For: Sep 30
Low
Report
Form 10-Q Stoke Therapeutics, Inc. For: Sep 30
11/5
07:05 am
stok
Form 8-K Stoke Therapeutics, Inc. For: Nov 05
Medium
Report
Form 8-K Stoke Therapeutics, Inc. For: Nov 05
11/4
01:57 pm
stok
Form SC 13G/A Stoke Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Stoke Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/25
Stoke Therapeutics (NASDAQ: STOK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
9.1%
3/23 Form 10-K Stoke Therapeutics, Inc. For: Dec 31 8.8%
2/14 Form SC 13G/A Stoke Therapeutics, Inc. Filed by: Cormorant Asset Management, LP 6.7%
10/2 Form 4 Stoke Therapeutics, Inc. For: Oct 01 Filed by: RTW INVESTMENTS, LP 6.6%
11/1 Form 4 Stoke Therapeutics, Inc. For: Oct 30 Filed by: WONG RODERICK 6.1%
9/30 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference 5.9%
8/14 Form 8-K Stoke Therapeutics, Inc. For: Aug 14 4.4%
4/15 Form 8-K Stoke Therapeutics, Inc. For: Apr 14 4.2%
8/1 Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference 4.1%
11/25 Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting 4.1%
3/23 Form 10-K Stoke Therapeutics, Inc. For: Dec 31 8.8%
2/14 Form SC 13G/A Stoke Therapeutics, Inc. Filed by: Cormorant Asset Management, LP 6.7%
10/2 Form 4 Stoke Therapeutics, Inc. For: Oct 01 Filed by: RTW INVESTMENTS, LP 6.6%
11/1 Form 4 Stoke Therapeutics, Inc. For: Oct 30 Filed by: WONG RODERICK 6.1%
9/30 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference 5.9%
8/14 Form 8-K Stoke Therapeutics, Inc. For: Aug 14 4.4%
4/15 Form 8-K Stoke Therapeutics, Inc. For: Apr 14 4.2%
8/1 Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference 4.1%
11/25 Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting 4.1%
TOP News Decliners
3/23
Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates
-11.7%
2/24 Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference -9.5%
12/23 Stoke Therapeutics Added to NASDAQ Biotechnology Index -8.4%
11/12 Stoke Therapeutics (NASDAQ: STOK) is now covered by analysts at BTIG Research. They set a "buy" rating and a $46.00 price target on the stock. -8.0%
10/16 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources -7.3%
10/8 Why Shares of Stoke Therapeutics Plummeted in September [The Motley Fool] -7.1%
9/11 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes -6.6%
6/21 Form 4 Stoke Therapeutics, Inc. For: Jun 21 Filed by: ATP III GP, Ltd. -6.5%
12/7 Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome -6.5%
9/18 Stoke Therapeutics (NASDAQ: STOK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.1%
2/24 Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference -9.5%
12/23 Stoke Therapeutics Added to NASDAQ Biotechnology Index -8.4%
11/12 Stoke Therapeutics (NASDAQ: STOK) is now covered by analysts at BTIG Research. They set a "buy" rating and a $46.00 price target on the stock. -8.0%
10/16 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources -7.3%
10/8 Why Shares of Stoke Therapeutics Plummeted in September [The Motley Fool] -7.1%
9/11 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes -6.6%
6/21 Form 4 Stoke Therapeutics, Inc. For: Jun 21 Filed by: ATP III GP, Ltd. -6.5%
12/7 Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome -6.5%
9/18 Stoke Therapeutics (NASDAQ: STOK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: